Scope and Claims Analysis of US Patent 7,524,834
Overview
US Patent 7,524,834, issued April 28, 2009, is assigned to Shire Development LLC. The patent covers a novel class of pharmaceutical formulations, specifically extended-release compositions containing methylphenidate for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related conditions.
Claims Summary
The patent contains 17 claims, which define the scope of the invention primarily focused on:
- Extended-release methylphenidate formulations
- Specific formulation parameters
- Manufacturing methods
Key Claims Breakdown
-
Independent Claim 1:
Defines an oral pharmacological composition comprising methylphenidate enclosed within a controlled-release matrix. The composition releases at least 80% of the methylphenidate over 10-14 hours. It specifies the composition's form as a compressed tablet with a specific matrix comprising a polymer and methylphenidate.
-
Dependent Claims 2-17:
Narrow the scope by specifying particular polymers, ratios, manufacturing processes, and release profiles. Examples include formulations with ethylcellulose or hydroxypropyl methylcellulose, release kinetics tailored to 12-hour profiles, and manufacturing by compression or extrusion.
Scope Details
- The patent primarily covers controlled-release oral methylphenidate formulations with particular release durations (8-14 hours).
- The claims focus on matrix systems using specific polymers to control release.
- Claims exclude immediate-release forms, implantable systems, and non-methylphenidate compositions.
Claim Coverage Analysis
- The broad independent claim covers formulations releasing most of the methylphenidate within a specified long duration.
- The claims do not specify individual polymer molecular weights or detailed manufacturing conditions, offering some flexibility.
- Narrower dependent claims limit scope to particular polymers and parameters, potentially susceptible to design-around strategies.
Patent Landscape
Prior Art Consideration
The patent landscape for methylphenidate formulations has been extensively studied due to significant commercial interest in ADHD medications. Prior patents include:
- US Patent 4,704,372 (1987): Early controlled-release methylphenidate formulations
- US Patent 5,659,011 (1997): Osmotic pump systems with methylphenidate
- US Patent 6,399,175 (2002): Extended-release methylphenidate with specific matrix systems
Novelty and Non-Obviousness
The patent claims over previous formulations focus on specific release profiles within a flexible polymer matrix system with tailored manufacturing methods. The novelty lies in the specific combination of release duration (8-14 hours) and the matrix composition.
Legal Status and Enforcement
- The patent was maintained from issuance through at least 2022.
- No notable litigation has been publicly disclosed relating specifically to this patent, suggesting limited legal challenges or litigation history.
Patent Family and Related Applications
- The patent family includes international counterparts: WO2006/044509 (PCT application filed in 2005).
- Files within Europe (EP) and Canada (CA) expand jurisdictional coverage.
Implications for Competitors
- Formulations with similar release profiles and matrices that fall within the scope of claims could infringe.
- Design-around strategies may involve changing polymers, manufacturing techniques, or release durations outside claimed parameters.
Conclusions
US Patent 7,524,834 provides a relatively broad coverage on extended-release methylphenidate compositions with a focus on specific polymer matrix systems. It sits within an established patent landscape but claims unique features related to release duration and matrix composition. Limited litigation history suggests effective claim defensibility or strategic patent positioning.
Key Takeaways
- The patent covers long-acting methylphenidate formulations optimizing a controlled-release profile.
- Claims are focused on polymer matrix compositions and release times between 8-14 hours.
- The patent's scope intersects with prior art but maintains novelty via specific release parameters.
- Competitors can potentially design around by altering polymers, matrices, or release profiles outside the claim scope.
- The patent family extends internationally, influencing global formulation strategies.
FAQs
1. What specific polymers are claimed in US Patent 7,524,834?
Claims specify polymers such as ethylcellulose and hydroxypropyl methylcellulose but without detailed molecular weight ranges, providing some flexibility.
2. How does this patent differ from earlier methylphenidate formulations?
It emphasizes a specific extended-release duration (8-14 hours) using particular matrix compositions, setting it apart from earlier immediate-release or different controlled-release systems.
3. Are there known legal challenges to this patent?
No publicly documented litigation indicates that the patent has not faced significant legal disputes.
4. What opportunities exist for formulators to avoid infringement?
Modifying the release duration outside 8-14 hours, using alternative polymers, or employing different manufacturing methods can circumvent claims.
5. How does this patent influence global methylphenidate patent strategies?
Its international family broadens geographical coverage, impacting formulations within jurisdictions like Europe and Canada.
References
- USPTO. Patent No. 7,524,834.
- US Patent & Trademark Office. Patent family data for WO2006/044509.
- European Patent Office. EP patent application corresponding to WO2006/044509.
- Prior art databases and patent search tools.
